Dr Marc Becker, PHD in Anaheim Hills, CA - Medicare Clinical Psychologist Provider

Dr Marc Becker, PHD is a medicare enrolled "Psychologist - Clinical" provider in Anaheim Hills, California. He graduated from medical school in 1981 and has 43 years of diverse experience with area of expertise as Clinical Psychologist. His current practice location is 5241 E Santa Ana Canyon Rd, Suite 130, Anaheim Hills, California. You can reach out to his office (for appointments etc.) via phone at (714) 637-0800.

Dr Marc Becker is licensed to practice in California (license number PSY10293) and he also participates in the medicare program. He accepts medicare assignments (which means he accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance) and his NPI Number is 1861429664.

Contact Information

	Dr Marc Becker, PHD
	5241 E Santa Ana Canyon Rd, Suite 130, Anaheim Hills, CA 92807-3737
	(714) 637-0800
	Not Available

Healthcare Provider's Profile

Full Name	Dr Marc Becker
Gender	Male
Speciality	Clinical Psychologist
Experience	43 Years
Location	5241 E Santa Ana Canyon Rd, Anaheim Hills, California
Accepts Medicare Assignments	Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance.

Medical Education and Training:

Dr Marc Becker graduated from medical school in 1981

NPI Data:

NPI Number: 1861429664
Provider Enumeration Date: 06/27/2006
Last Update Date: 01/15/2012

Medicare PECOS Information:

PECOS PAC ID: 7416114079
Enrollment ID: I20120209000193

Medical Identifiers

Medical identifiers for Dr Marc Becker such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1861429664	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
103TC0700X	Psychologist - Clinical	PSY10293 (California)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Dr Marc Becker is enrolled with medicare and thus, if eligible, can prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Dr Marc Becker, PHD 5241 E Santa Ana Canyon Rd, Suite 130, Anaheim Hills, CA 92807-3737 Ph: (714) 637-0800	Dr Marc Becker, PHD 5241 E Santa Ana Canyon Rd, Suite 130, Anaheim Hills, CA 92807-3737 Ph: (714) 637-0800

News Archive

Researchers investigate mechanism of immune system to decipher gut-dwelling worms

A billion people living in underdeveloped areas around the world are infected with parasitic helminthes, worms that survive by residing in and feeding on their hosts. These infestations can cause chronic intestinal (and occasionally systemic) illnesses leading to long-term disability. Irah King and Markus Mohrs, biomedical researchers at the Trudeau Institute, are investigating illnesses caused by these gut-dwelling worms in an effort to decipher how immune cells send and receive signals that determine the specific immune response to mount.

Transvaginal ultrasound effective in treating early-stage endometrial cancer

A common birth control device is effective in treating early-stage endometrial cancer in morbidly obese and high-risk surgery patients, said Georgia Health Sciences University Cancer Center researchers, and could lead to a cost-effective treatment for all women with this cancer type.

Black patients face higher death rates in early stages of kidney disease

Black patients are more likely to die in the early stages of chronic kidney disease than whites, according to a new study by a Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed) researcher and his team that will be published in the July issue of the Journal of the American Society of Nephrology.

Biogen Idec, Swedish Orphan Biovitrum present results from rFIXFc Phase 1/2a study in hemophilia B

Biogen Idec and Swedish Orphan Biovitrum AB today announced results from a Phase 1/2a open-label, dose-escalation, safety and pharmacokinetic study of the companies' long-lasting, fully-recombinant factor IX Fc fusion protein (rFIXFc) in hemophilia B patients. The data, which were presented at the World Federation of Hemophilia Congress in Buenos Aires, Argentina, on July 11, 2010, showed that rFIXFc was well tolerated and demonstrated an approximately three-fold increase in half-life compared to historical data for existing therapies.

Pfizer, Wyeth and PF Prism file suit against Watson over generic Pristiq

Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc. - Florida, filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Desvenlafaxine Succinate Extended-release Tablets, 50 mg and 100 mg.

Dr Marc Becker, PHD - Medicare Psychologist in Anaheim Hills, CA